US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nasus Pharma Ltd.

7.95

+0.06000.76%

Volume:2.02K

Turnover:16.35K

Market Cap:72.05M

PE:-36.47

High:8.20

Open:7.92

Low:7.92

Close:7.89

52wk High:9.99

52wk Low:5.90

Shares:9.06M

Float Shares:3.98M

Volume Ratio:2.11

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2180

EPS(LYR):-0.2180

ROE:--

ROA:-116.06%

PB:-22.43

PE(LYR):-36.47

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Nasus Pharma Expands Collaboration with Aptar for Intranasal Epinephrine Program

BRIEF-Nasus Pharma Announces Expanded Agreement To Support Development And Commercialization Of Ns002 Intranasal Epinephrine Program

Nasus Pharma announces expanded agreement to support NS002

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of Ns002 Intranasal Epinephrine Program

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NSRX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":7.95,"timestamp":1761595200000,"preClose":7.89,"halted":0,"volume":2022,"delay":0,"floatShares":3982680,"shares":9063458,"eps":-0.217993,"marketStatus":"Pre-Mkt","change":0.06,"latestTime":"10-28 06:00:12 EDT","open":7.92,"high":8.2,"low":7.92,"amount":16351.7311,"amplitude":0.035488,"askPrice":8.95,"askSize":605,"bidPrice":3.32,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.217993,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1761658200000},"marketStatusCode":1,"adr":0,"listingDate":1755057600000,"exchange":"NASDAQ","adjPreClose":7.95,"volumeRatio":2.106688586230046},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":3982680,"roa":"-116.06%","roe":"--","lyrEps":-0.217993,"volumeRatio":2.106688586230046,"shares":9063458,"dividePrice":0,"high":8.2,"amplitude":0.035488,"preClose":7.89,"low":7.92,"week52Low":5.9,"pbRate":"-22.43","week52High":9.9899,"institutionHeld":0,"latestPrice":7.95,"committee":-0.716312,"eps":-0.217993,"divideRate":0,"volume":2022,"delay":0,"ttmEps":-0.217993,"open":7.92,"prevYearClose":8,"prevWeekClose":7.89,"prevMonthClose":6.65,"prevQuarterClose":6.65,"fiveDayClose":7.6701,"twentyDayClose":7.55,"sixtyDayClose":8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1759377600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2025-10-27","current":-36.469061,"percent":0.666667,"low":-51.389177,"twenty":-47.876499,"median":-47.311455,"eighty":-45.00249,"high":-35.481595,"avg":-46.280259,"sd":3.013722,"marketCap":71480512},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-27","current":-46.658298,"twenty":-47.876499,"median":-47.311455,"eighty":-45.00249,"marketCap":71480512}],"updateTime":1761645613007},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2573286929","title":"Nasus Pharma Expands Collaboration with Aptar for Intranasal Epinephrine Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2573286929","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573286929?lang=en_us&edition=fundamental","pubTime":"2025-10-08 21:27","pubTimestamp":1759930067,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Nasus Pharma Ltd. ( ($NSRX) ). On October 6, 2025, Nasus Pharma Ltd. extended its collaboration with AptarGroup...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-expands-collaboration-with-aptar-for-intranasal-epinephrine-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-expands-collaboration-with-aptar-for-intranasal-epinephrine-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2573923136","title":"BRIEF-Nasus Pharma Announces Expanded Agreement To Support Development And Commercialization Of Ns002 Intranasal Epinephrine Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923136","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923136?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:25","pubTimestamp":1759926337,"startTime":"0","endTime":"0","summary":"BRIEF-Nasus Pharma Announces Expanded Agreement To Support Development And Commercialization Of Ns002 Intranasal Epinephrine ProgramOct 8 (Reuters) - Nasus Pharma Ltd NSRX.A:NASUS PHARMA ANNOUNCES EXP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA1RR9JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2573923948","title":"Nasus Pharma announces expanded agreement to support NS002","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923948?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:17","pubTimestamp":1759925823,"startTime":"0","endTime":"0","summary":"Nasus Pharma (NSRX) announced the execution of comprehensive agreements with Aptar France S.A.S. and AptarGroup (ATR) to support the ongoing clinic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-announces-expanded-agreement-to-support-ns002-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-announces-expanded-agreement-to-support-ns002-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX","BK4126","ATR"],"gpt_icon":0},{"id":"2573282659","title":"Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of Ns002 Intranasal Epinephrine Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2573282659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573282659?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:04","pubTimestamp":1759925040,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUA1RR9JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NSRX\",params:#limit:6,delay:false,,,undefined,":[]}}